3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Fluorouracil
10
Oxaliplatin
8
Capecitabine
7
Specimen Handling
6
Nivolumab
6
Leucovorin
6
trastuzumab deruxtecan
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
4
fludarabine
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Biopsy
4
aldesleukin
3
Trastuzumab
3
zimberelimab
2
ulixertinib
2
fludarabine phosphate
2
Ramucirumab
2
Irinotecan
2
Folfox protocol
2
zolbetuximab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.